Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Seminari

Showing results (11-20 of 30) with videos related to

Pageof 3
Sort By:
AIDS (London, England)|June 5, 1999
High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic diseaseR Maserati, P Villani, E Seminari, et al.
Antiviral Therapy|May 7, 2003
Antiretroviral effect of two different dose regimens of ritonavir and saquinavir on HIV-infected adults in a population-based settingN Jahnke, E Seminari, R S Hogg, et al.
British Journal of Clinical Pharmacology|December 14, 1999
Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patientsP Villani, M B Regazzi, F Castelli, et al.
Journal of Chemotherapy (Florence, Italy)|January 5, 2002
Nelfinavir suspension obtained from nelfinavir tablets has equivalent pharmacokinetic profileM B Regazzi, E Seminari, P Villani, et al.
The Journal of Antimicrobial Chemotherapy|March 7, 2000
Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patientsM B Regazzi, P Villani, R Maserati, et al.
Therapeutic Drug Monitoring|June 12, 1999
High-performance liquid chromatography method for analyzing the antiretroviral agent efavirenz in human plasmaP Villani, M Pregnolato, S Banfo, et al.
Atherosclerosis|May 9, 2002
Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitorsE Seminari, A Pan, G Voltini, et al.
AIDS Research and Human Retroviruses|October 9, 1999
Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parametersF Lori, E Rosenberg, J Lieberman, et al.
AIDS (London, England)|December 20, 2003
Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patientsMonica Guffanti, Cleta Raffaella De Pascalis, E Seminari, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 29, 2000
Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV-1-positive patients heavily pretreated with nucleoside analogues and protease inhibitorsE Seminari, F Maggiolo, P Villani, et al.
Pageof 3

Showing results (11-20 of 30) with videos related to

Sort By:
Pageof 3
AIDS (London, England)|June 5, 1999
High plasma levels of nelfinavir and efavirenz in two HIV-positive patients with hepatic diseaseR Maserati, P Villani, E Seminari, et al.
Antiviral Therapy|May 7, 2003
Antiretroviral effect of two different dose regimens of ritonavir and saquinavir on HIV-infected adults in a population-based settingN Jahnke, E Seminari, R S Hogg, et al.
British Journal of Clinical Pharmacology|December 14, 1999
Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patientsP Villani, M B Regazzi, F Castelli, et al.
Journal of Chemotherapy (Florence, Italy)|January 5, 2002
Nelfinavir suspension obtained from nelfinavir tablets has equivalent pharmacokinetic profileM B Regazzi, E Seminari, P Villani, et al.
The Journal of Antimicrobial Chemotherapy|March 7, 2000
Clinical pharmacokinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patientsM B Regazzi, P Villani, R Maserati, et al.
Therapeutic Drug Monitoring|June 12, 1999
High-performance liquid chromatography method for analyzing the antiretroviral agent efavirenz in human plasmaP Villani, M Pregnolato, S Banfo, et al.
Atherosclerosis|May 9, 2002
Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitorsE Seminari, A Pan, G Voltini, et al.
AIDS Research and Human Retroviruses|October 9, 1999
Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parametersF Lori, E Rosenberg, J Lieberman, et al.
AIDS (London, England)|December 20, 2003
Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patientsMonica Guffanti, Cleta Raffaella De Pascalis, E Seminari, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 29, 2000
Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV-1-positive patients heavily pretreated with nucleoside analogues and protease inhibitorsE Seminari, F Maggiolo, P Villani, et al.
Pageof 3